Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 756 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Retinal Disease, Glaucoma
Interventions: Not listed
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 4
States / cities: Bronxville, New York • New York, New York

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: PF-04217329, latanoprost vehicle, latanoprost; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 8
States / cities: Cypress, California • Garden Grove, California • Gardena, California + 4 more

Conditions: Glaucoma
Interventions: HOCD; Device
Lead sponsor: Benjamin Frankfort, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Assess Eye Measurements in Patients Having Retina Pathology or Glaucoma
Interventions: Not listed
Lead sponsor: Optovue; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Daly City, California • Petaluma, California • Walnut Creek, California

Conditions: Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
Interventions: Visual Performance tests, Brain-computer interface; Diagnostic Test · Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 90 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Glaucoma, Ocular Hypertension
Interventions: Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Open Angle Glaucoma
Interventions: OMNI Surgical System; Device
Lead sponsor: Mark Gallardo, MD; Other
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Ocular Hypertension
Interventions: Latanoprostene Bunod, Placebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Normal Tension Glaucoma (NTG)
Interventions: QLS-101, Timolol maleate PF 0.5% ophthalmic solution; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Glaucoma, Application Site Pigmentation Changes
Interventions: latanoprost, bimatoprost, travoprost; Drug
Lead sponsor: Summa Health System; Other
Eligibility: 30 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Arlington Heights, Illinois • Akron, Ohio

Conditions: Glaucoma
Interventions: Needle fenestration, Suture wick; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
Interventions: Hydrus Microstent, iStent Trabecular Micro Bypass; Device
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years to 84 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Irvine, California

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Interventions: Direct Selective laser Trabeculoplasty; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
Interventions: QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, timolol maleate 0.5%, latanoprost 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 42
States / cities: Sun City, Arizona • Glendale, California • Inglewood, California + 38 more

Conditions: Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg; Device · Drug
Lead sponsor: Jonathon Myers; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open Angle Glaucoma
Interventions: Hydrus Aqueous Implant, Cataract surgery; Device · Procedure
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 23 more

Conditions: Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions: H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%; Drug
Lead sponsor: D. Western Therapeutics Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more

Conditions: Glaucoma, Open-Angle
Interventions: Standard Automatic Perimetry Humphrey Field Analyzer, visuALL Field Analyzer; Diagnostic Test
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: EyeSimplify web-browser-based visual field test; Device
Lead sponsor: Andrew Pouw, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Glaucoma
Interventions: Beacon Aqueous Microshunt; Device
Lead sponsor: MicroOptx; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Grand Junction, Colorado • Bloomington, Minnesota • Dayton, Ohio

Conditions: OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions: QLS-111-FDC, Latanoprost (0.005%); Combination Product · Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Largo, Florida

Conditions: Ocular Hypertension
Interventions: CATS tonometer prism, Goldmann tonometer prism; Device
Lead sponsor: Intuor Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Topcon 3D OCT-1000 Optical Coherence Tomography System

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

Human Optokinetic Contrast Device (HOCD) to Measure Visual Function and Identify Patients With and Without Glaucoma

Evaluation of OCT Measurements

BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases

Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

A Single Center Proof Of Concept Study To Assess Intra And Perioperative Safety Profile Of OMNI Surgical System

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period

Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes

Direct vs Standard SLT for Glaucoma: A Noninferiority Trial

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry

Persistence of Glaucoma Patients With Web-Browser-Based Visual Field Test

Study of the Beacon Aqueous Microshunt in Patients With Refractory Glaucoma

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

Clinical Evaluation of CATS Tonometer Prism